123 related articles for article (PubMed ID: 37257580)
1. The expression IL1B correlates negatively with the clinical response to adalimumab in Crohn's disease patients: An ex vivo approach using peripheral blood mononuclear cells.
Gole B; Pernat C; Jezernik G; Potočnik U
Life Sci; 2023 Aug; 326():121822. PubMed ID: 37257580
[TBL] [Abstract][Full Text] [Related]
2. Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-α treatment in patients with Crohn's disease.
Dige A; Magnusson MK; Öhman L; Hvas CL; Kelsen J; Wick MJ; Agnholt J
Scand J Gastroenterol; 2016; 51(6):692-9. PubMed ID: 26784676
[TBL] [Abstract][Full Text] [Related]
3. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
[TBL] [Abstract][Full Text] [Related]
4. Activity of SHIP, Which Prevents Expression of Interleukin 1β, Is Reduced in Patients With Crohn's Disease.
Ngoh EN; Weisser SB; Lo Y; Kozicky LK; Jen R; Brugger HK; Menzies SC; McLarren KW; Nackiewicz D; van Rooijen N; Jacobson K; Ehses JA; Turvey SE; Sly LM
Gastroenterology; 2016 Feb; 150(2):465-76. PubMed ID: 26481854
[TBL] [Abstract][Full Text] [Related]
5. Crohn's Disease Patients with Depression Exhibit Alterations in Monocyte/Macrophage Phenotype and Increased Proinflammatory Cytokine Production.
Tang Y; Zhao L; Lei N; Chen P; Zhang Y
Dig Dis; 2020; 38(3):211-221. PubMed ID: 31216541
[TBL] [Abstract][Full Text] [Related]
6. Omics data integration identifies ELOVL7 and MMD gene regions as novel loci for adalimumab response in patients with Crohn's disease.
Gorenjak M; Zupin M; Jezernik G; Skok P; Potočnik U
Sci Rep; 2021 Mar; 11(1):5449. PubMed ID: 33750834
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of chemokine network by biologic monotherapy in ileum of patients with Crohn's disease.
Linares R; Gutiérrez A; Márquez-Galera Á; Caparrós E; Aparicio JR; Madero L; Payá A; López-Atalaya JP; Francés R
Biomed Pharmacother; 2022 Mar; 147():112653. PubMed ID: 35078095
[TBL] [Abstract][Full Text] [Related]
8. Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn's Disease.
Mitsialis V; Wall S; Liu P; Ordovas-Montanes J; Parmet T; Vukovic M; Spencer D; Field M; McCourt C; Toothaker J; Bousvaros A; ; ; Shalek AK; Kean L; Horwitz B; Goldsmith J; Tseng G; Snapper SB; Konnikova L
Gastroenterology; 2020 Aug; 159(2):591-608.e10. PubMed ID: 32428507
[TBL] [Abstract][Full Text] [Related]
9. Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease.
Lykowska-Szuber L; Walczak M; Skrzypczak-Zielinska M; Suszynska-Zajczyk J; Stawczyk-Eder K; Waszak K; Eder P; Wozniak A; Krela-Kazmierczak I; Slomski R; Dobrowolska A
Front Immunol; 2021; 12():615539. PubMed ID: 33767696
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
11. The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - an immunohistochemical study.
Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Zabel M; Linke K
J Crohns Colitis; 2013 Oct; 7(9):706-16. PubMed ID: 23021876
[TBL] [Abstract][Full Text] [Related]
12. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study.
Marín-Jiménez I; Acosta MB; Esteve M; Castro-Laria L; García-López S; Ceballos D; Echarri A; Martín-Arranz MD; Busquets D; Llaó J; Navarro-Llavat M; Huguet JM; Argüelles-Arias F; Vicente R; Boudet JM; Díaz G; Sánchez-Migallón AM; Casellas F;
Gastroenterol Hepatol; 2022 Mar; 45(3):165-176. PubMed ID: 34051313
[TBL] [Abstract][Full Text] [Related]
13. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
[TBL] [Abstract][Full Text] [Related]
14. Infliximab therapy increases the frequency of circulating CD16(+) monocytes and modifies macrophage cytokine response to bacterial infection.
Nazareth N; Magro F; Silva J; Duro M; Gracio D; Coelho R; Appelberg R; Macedo G; Sarmento A
Clin Exp Immunol; 2014 Sep; 177(3):703-11. PubMed ID: 24816497
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab for maintenance of remission in Crohn's disease.
Townsend CM; Nguyen TM; Cepek J; Abbass M; Parker CE; MacDonald JK; Khanna R; Jairath V; Feagan BG
Cochrane Database Syst Rev; 2020 May; 5(5):CD012877. PubMed ID: 32413933
[TBL] [Abstract][Full Text] [Related]
16. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease.
Mortensen JH; van Haaften WT; Karsdal MA; Bay-Jensen AC; Olinga P; Grønbæk H; Hvas CL; Manon-Jensen T; Dijkstra G; Dige A
J Clin Gastroenterol; 2021 Jan; 55(1):59-66. PubMed ID: 32301833
[TBL] [Abstract][Full Text] [Related]
17. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
[TBL] [Abstract][Full Text] [Related]
18. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
19. Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways.
Luther J; Gala M; Patel SJ; Dave M; Borren N; Xavier RJ; Ananthakrishnan AN
Dig Dis Sci; 2018 Mar; 63(3):738-745. PubMed ID: 29372477
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease.
Veerappan SG; Healy M; Walsh BJ; O'Morain CA; Daly JS; Ryan BM
Dig Dis Sci; 2015 Jul; 60(7):2119-29. PubMed ID: 25732718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
